P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer

Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):665-673. doi: 10.1080/21691401.2019.1576702.

Abstract

The present study was aimed to develop an effective nanoliposomal vaccine delivery system with P435 HER2/neu-derived peptide conjugated to Maleimide-PEG2000-DSPE. The nanoliposome formulation composed of DSPC/DSPG/Chol/DOPE and monophosphoryl lipid A was used as an adjuvant. Liposomal formulations were prepared and their physical properties were characterized. Anti-tumoral efficacy of formulations was evaluated by immunization of tumor-bearing BALB/c mice and the generated immune response was studied by using ELISpot and flow cytometry analysis. The results of the study demonstrated Lip + DOPE + P535 formulation caused the lowest tumor size and the longest survival time in TUBO mice model and could make it a promising candidate in developing effective vaccines against HER2-positive breast cancers.

Keywords: HER2/neu protein; P435 peptide; Peptide-conjugated nanoliposomes; breast cancer; cytotoxic T-cell response; prophylactic vaccine.

MeSH terms

  • Animals
  • Cancer Vaccines* / chemistry
  • Cancer Vaccines* / immunology
  • Cancer Vaccines* / pharmacology
  • Cell Line, Tumor
  • Female
  • Liposomes
  • Mammary Neoplasms, Experimental* / immunology
  • Mammary Neoplasms, Experimental* / prevention & control
  • Mice, Inbred BALB C
  • Nanoparticles* / chemistry
  • Nanoparticles* / therapeutic use
  • Peptides* / chemistry
  • Peptides* / immunology
  • Peptides* / pharmacology
  • Receptor, ErbB-2* / chemistry
  • Receptor, ErbB-2* / immunology
  • Receptor, ErbB-2* / therapeutic use

Substances

  • Cancer Vaccines
  • Liposomes
  • Peptides
  • Erbb2 protein, mouse
  • Receptor, ErbB-2